BPC-157 vs TB-500
Two of the most-discussed recovery peptides. They are often stacked rather than chosen against each other, and neither is FDA-approved; human evidence is limited for both.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Gastric-juice-derived pentadecapeptide | Thymosin beta-4 fragment |
| Proposed action | Angiogenesis, growth-factor receptor upregulation, gut and tendon repair | Actin regulation, angiogenesis, wound healing |
| Evidence | Mostly preclinical; limited human data | Mostly preclinical; limited human data |
| Dosing cadence | Short half-life; often dosed daily | Longer-acting; often dosed a few times weekly |
Lean toward BPC-157 when
- Localized gut, tendon, or ligament repair is the focus
- You want the more-studied of the two in injury models
Lean toward TB-500 when
- Systemic recovery is the focus
- Less-frequent dosing is preferred
Verdict
No head-to-head human trials exist. Both are investigational with limited human evidence and are frequently combined (the 'BPC/TB stack') rather than chosen against each other. Educational only; not approved, consult a clinician.
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.